Drug sensitivity analysis (A) Correlation between sensitivity to cabozantinib and pazopanib and the expression of E2F7. (B) Predicted IC50 values of sorafenib, sunitinib, pazopanib, and axitinib between the E2F7high and E2F7low groups. (C) Effectiveness of sunitinib, pazopanib, and cabozantinib in the si-E2F7 and si-NC groups of OSRC-2 and 786-O cells. Detection of p-VEGFR2 and VEGFR2 expression (D) and p-AKT and AKT expression (E) in OSRC-2 and 786-O cells after E2F7 knockdown.